Treatment Options After CAR T Therapy for Large B-Cell Lymphoma

Video

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

This content originally appeared on our sister site, OncLive.

Related Videos
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Related Content
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center

First Patient With Gastric Cancer Dosed in iNKT/CTLA-4 Inhibitor/Anti-PD-L1 Trial

April 24th 2024
Article

A case study previously described successful immune modulation with AgenT-797 in a patient with high-risk gastric cancer leading to a partial response.

European Commission Approves Janssen and Legend Biotech’s Carvykti for Expanded Indication in Earlier Line Multiple Myeloma

European Commission Approves Janssen and Legend Biotech’s Carvykti for Expanded Indication in Earlier Line Multiple Myeloma

April 23rd 2024
Article

The EC’s decision comes several weeks after the FDA approved cilta-cel for a similar expanded indication.

EGFR-Targeting γδ2T-Cell Cleared for Solid Tumor Trial

EGFR-Targeting γδ2T-Cell Cleared for Solid Tumor Trial

April 22nd 2024
Article

Acepodia is also evaluating a CD20-targeted γδ2T-cell therapy in patients with non-Hodgkin lymphoma.

Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic

Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective

April 20th 2024
Article

Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.

CGTLive®’s Weekly Rewind – April 19, 2024

CGTLive®’s Weekly Rewind – April 19, 2024

April 19th 2024
Article

Review top news and interview highlights from the week ending April 19, 2024.

FDA to Investigate Risk of T-Cell Malignancy After CAR T-Cell Therapy

FDA Requires Boxed Warnings for Secondary Cancer for Approved CAR-T Therapies

April 19th 2024
Article

The FDA has requested that black box warnings related to secondary cancer risks be added to all 6 CAR-T therapies currently on the market.

© 2024 MJH Life Sciences

All rights reserved.